Edition: United Kingdom  
One News Page
“Probably the fastest-access news portal in the world”
Actelion News 
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 

New cancer drugs help Johnson & Johnson top profit estimates

(Reuters) - Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30..
Reuters

Strong drug sales, Actelion buy power J&J's profit beat

(Reuters) - Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast, driven by strong demand for its new cancer drugs and gains from its acquisition of..
Reuters

Videos for actelion

News video: J&J CEO Gorsky on M&A, Health Care, Tax Reform

J&J CEO Gorsky on M&A, Health Care, Tax Reform 15:01

Jun.26 -- Alex Gorsky, chairman and chief executive officer at Johnson & Johnson, discusses the company’s purchase of Actelion, the state of health care in the United States, and what tax reform..
Source: Bloomberg Politics -

News video: January a Banner Month for Global M&A Despite Uncertainty

January a Banner Month for Global M&A Despite Uncertainty 03:20

Feb.06 -- Bloomberg’s Jeff McCracken discusses global deal activity in January, President Trump’s tax proposals and mergers and acquisitions in an unpredictable market. He speaks on “Bloomberg..
Source: Bloomberg Global Business -

News video: Weekly Wrap: Dow Hits 20,000, J&J Looks for Growth

Weekly Wrap: Dow Hits 20,000, J&J Looks for Growth 02:39

We look at what the Dow's new milestone means for investors. Plus, Johnson & Johnson looks to boost its prospects, and United Technologies looks cheap.
Source: Morningstar.com -

News video: J&J Acquires Actelion for $$30 Billion

J&J Acquires Actelion for $$30 Billion 02:15

Jan.26 -- Bloomberg’s Jeffrey McCracken reports on Johnson & Johnson’s $30 billion acquisition of Actelion. He speaks on “Bloomberg Markets.”
Source: Bloomberg Global Business -

News video: Those Who Benefit From Johnson & Johnson Takeovers

Those Who Benefit From Johnson & Johnson Takeovers 00:31

Johnson & Johnson is enacting at $30 billion takeover of Europe’s biggest biotech company, Actelion. Johnson & Johnson is known for buying Swiss medical companies, and those who own stock in the..
Source: Wochit Headline News -

 

J&J reports 11.9 percent fall in quarterly profit

(Reuters) - Johnson & Johnson , which completed its $30 billion acquisition of Swiss biotech Actelion in June, reported a 11.9 percent fall in quarterly profit as costs rose.
Reuters

Johnson & Johnson reports dip in quarterly profit

(Reuters) - Johnson & Johnson , which completed its $30 billion acquisition of Swiss biotech Actelion last month, reported a 4.3 percent fall in quarterly profit, as costs rose.
Reuters

Actelion spin-off Idorsia up 30% on market debut

Pharma group valued at SFr1.5bn despite no significant revenues expected for 3 years
FT.com

EU approves Johnson & Johnson's $30bn purchase of Actelion

eu approves johnson & johnson's $30bn purchase of actelion
The European Commission today approved the planned sale of Swiss pharmaceuticals firm Actelion to Johnson & Johnson (J&J), subject to conditions. EU regulators qualified the sale of Europe's biggest..
City A.M.

J&J garners EU approval for $30bn Actelion deal


FT.com

EU approves J&J purchase of Actelion subject to conditions

BRUSSELS (Reuters) - EU antitrust regulators approved on Friday Johnson & Johnson's planned purchase of Actelion Pharmaceutical subject to conditions intended to ensure clinical development of insomnia..
Reuters

Actelion antibiotic misses mark on one study, hits it on another

ZURICH (Reuters) - Swiss biotechnology company Actelion on Thursday presented mixed trial results for its antibiotic hopeful cadazolid, saying it met the main goal of one late-stage study but failed to..
Reuters

J&J's quarterly sales rise 1.6 percent

(Reuters) - Johnson & Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday a 1.6 percent rise in first-quarter sales.
Reuters

EMA gives green light to Actelion's Uptravi after safety review

ZURICH (Reuters) - The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion's Uptravi, saying a review after five patient deaths in France did not suggest an..
Reuters

J&J declares Actelion tender offer a success, sees closing in second quarter

ZURICH (Reuters) - Johnson & Johnson declared its $30 billion tender offer for Swiss biotechnology company Actelion successful on Friday, reporting it controlled 77.2 percent of the voting rights after..
Reuters

It's official: Deal volumes hit highest level since the financial crisis

it's official: deal volumes hit highest level since the financial crisis
Global M&A activity so far this year is at its highest level since the financial crisis, expert analysis has revealed. Some $705bn of deals have been announced since the start of 2017, the first..
City A.M.

Actelion, being bought by J&J, says full year profit rose 26 percent

ZURICH (Reuters) - Swiss drugmaker Actelion said on Tuesday that its full year 2016 net income rose 26 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial..
Reuters


You Might Like


 ⏮️  Page 1  ⏩ 
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+